Moller Financial Services bought a new position in Merck & Company, Inc. (NYSE:MRK) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 4,930 shares of the company’s stock, valued at approximately $316,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. HM Capital Management LLC increased its stake in shares of Merck & by 0.4% in the first quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock worth $236,000 after buying an additional 15 shares during the period. RB Capital Management LLC increased its stake in shares of Merck & by 0.5% in the second quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock worth $294,000 after buying an additional 23 shares during the period. Baystate Wealth Management LLC increased its stake in shares of Merck & by 0.4% in the second quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock worth $405,000 after buying an additional 27 shares during the period. Bath Savings Trust Co increased its stake in shares of Merck & by 0.5% in the second quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock worth $348,000 after buying an additional 28 shares during the period. Finally, Camelot Portfolios LLC increased its stake in shares of Merck & by 0.4% in the first quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock worth $494,000 after buying an additional 33 shares during the period. 72.86% of the stock is currently owned by institutional investors.
Shares of Merck & Company, Inc. (NYSE:MRK) opened at 58.24 on Monday. The stock has a market capitalization of $158.84 billion, a P/E ratio of 31.53 and a beta of 0.80. Merck & Company, Inc. has a 52-week low of $57.82 and a 52-week high of $66.80. The stock has a 50 day moving average of $64.26 and a 200-day moving average of $63.65.
Merck & (NYSE:MRK) last announced its quarterly earnings results on Friday, October 27th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $1.03 by $0.08. The firm had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. Merck & had a return on equity of 26.82% and a net margin of 11.60%. The business’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.07 earnings per share. Analysts predict that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.
Several research analysts recently commented on MRK shares. Cowen and Company reaffirmed a “hold” rating and issued a $70.00 target price on shares of Merck & in a research note on Friday, September 1st. Zacks Investment Research downgraded shares of Merck & from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC reaffirmed a “sell” rating and issued a $55.00 target price on shares of Merck & in a research note on Friday, October 20th. BMO Capital Markets set a $70.00 target price on shares of Merck & and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Finally, Leerink Swann boosted their price objective on shares of Merck & from $69.00 to $70.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $70.00.
COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.com-unik.info/2017/10/30/moller-financial-services-takes-316000-position-in-merck-company-inc-mrk.html.
Merck & Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).
What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.